Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,062 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anemia Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Nutritional Outcomes After Vitamin A Supplementation in Subjects With SCD

NCT03632876
View directory record Official record
Conditions
Sickle Cell Anemia in Children, Vitamin A Deficiency in Children
Interventions
retinyl palmitate
Dietary Supplement
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
9 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 20, 2026, 6:31 AM EDT
Terminated Phase 1Phase 2 Interventional

TRF-1101 Assessment in Sickle Cell Disease

NCT00773890
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
TRF-1101, Placebo
Drug
Lead sponsor
TRF Pharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Augusta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2009 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Not applicable Interventional Results available

Cognitive Behavioral Therapy and Real-Time Pain Management Intervention for Sickle Cell Via Mobile Applications

NCT04419168
View directory record Official record
Conditions
Chronic Pain, Depression, Anxiety, Opioid Use
Interventions
cCBT, m-Education
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Chicago, Illinois • Baltimore, Maryland • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT02680574
View directory record Official record
Conditions
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
219
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 158 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment

NCT00447694
View directory record Official record
Conditions
Beta-thalassemia, Iron Overload
Interventions
Deferasirox
Drug
Lead sponsor
Novartis
Industry
Eligibility
10 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

NCT00002502
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, cytarabine, allogeneic bone marrow transplantation
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 20, 2026, 6:31 AM EDT
Active, not recruiting Phase 2 Interventional

Bevacizumab In Hereditary Hemorrhagic Telangiectasia

NCT04404881
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Bevacizumab (Avastin®)
Drug
Lead sponsor
Hanny Al-Samkari, MD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

NCT04313153
View directory record Official record
Conditions
Anemia
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Chula Vista, California • Granada Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 20, 2026, 6:31 AM EDT
Recruiting Phase 1 Interventional

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

NCT06458712
View directory record Official record
Conditions
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Interventions
DSB2455
Drug
Lead sponsor
Duke Street Bio Ltd
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Sacramento, California • New Haven, Connecticut • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

NCT00440466
View directory record Official record
Conditions
Anemia, Renal Diseases
Interventions
epoetin alfa
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
66
States / cities
Chula Vista, California • Fountain Valley, California • Los Angeles, California + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 20, 2026, 6:31 AM EDT
Withdrawn Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP

NCT04039477
View directory record Official record
Conditions
Autoimmune Hemolytic Anemia, Immune Thrombocytopenia
Interventions
KZR-616
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 20, 2026, 6:31 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

NCT05031780
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Mitapivat, Mitapivat-matching placebo
Drug · Other
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
16 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
28
States / cities
La Jolla, California • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 4 Interventional

Low Dose Ketamine and Acute Pain Crisis

NCT04330183
View directory record Official record
Conditions
Sickle Cell Crisis
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 20, 2026, 6:31 AM EDT
Not listed Phase 1 Interventional

PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

NCT00343954
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
L-citrulline tablets, 1000 mg
Drug
Lead sponsor
Angiogenix
Industry
Eligibility
10 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2006 · Synced Oct 20, 2026, 6:31 AM EDT
Terminated Phase 1Phase 2 Interventional

Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)

NCT02093429
View directory record Official record
Conditions
MDS (Myelodysplastic Syndrome)
Interventions
INCB047986
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Highland, California • Indianapolis, Indiana • Morristown, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia

NCT01703169
View directory record Official record
Conditions
Severe Aplastic Anemia, Very Severe Aplastic Anemia, Moderate Aplastic Anemia
Interventions
Eltrombopag
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 20, 2026, 6:31 AM EDT
Terminated Phase 4 Interventional Results available

Prevalence and Treatment of Anemia in Rehabilitation Patients

NCT00511901
View directory record Official record
Conditions
Anemia
Interventions
placebo, epoetin alpha, Niferex
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
60 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Cranbury, New Jersey • East Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Not applicable Interventional

Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators

NCT02197845
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Patient Navigator, Recruitment into Specialty Care
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
15 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 20, 2026, 6:31 AM EDT
Terminated No phase listed Observational

Etiology of Anemia

NCT00302939
View directory record Official record
Conditions
Anemia
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 20, 2026, 6:31 AM EDT
Terminated No phase listed Observational

Automated Myocardial Performance Index Using Samsung HERA W10

NCT04140669
View directory record Official record
Conditions
Twin to Twin Transfusion Syndrome, Congenital Diaphragmatic Hernia, Neural Tube Defects, Lower Urinary Tract Infection
Interventions
Automated Myocardial Performance Index (MPI)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 1 Interventional

Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia

NCT00004245
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
sodium salicylate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

NCT01419977
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Placebo, Dalteparin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic

NCT00002303
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 6:31 AM EDT
Not listed Not applicable Interventional

iPeer2Peer Program for Youth With Sickle Cell Disease

NCT03989986
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
iPeer2Peer Mentorship
Behavioral
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
12 Years to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 20, 2026, 6:31 AM EDT